Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Cutrell, Amy; Schapiro, Jonathan; Federico Perno, Carlo; R. Kuritzkes, Daniel; Quercia, Romina; Patel, Parul; W. Polli, Joseph; Dorey, David; Wang, Yongwei; Wu, Sterling; Van Eygen, Veerle; Crauwels, Herta; L. Ford, Susan; Baker, Mark; L. Talarico, Christine; St. Clair, Marty; L. Jeffrey, Jerry; White, Carl; Vanveggel, Simon; Vandermeulen, Kati; A. Margolis, David; Aboud, Michael; Spreen, William; van Lunzen, Jan

doi:10.1097/qad.0000000000002883

Public

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis

Published in AIDS • Mar 17, 2021

Authors:

Amy Cutrell

Jonathan Schapiro

Carlo Federico Perno

Abstract

OBJECTIVE: Efficacy and safety of long-acting cabotegravir (CAB) and rilpivirine (RPV) dosed intramuscularly every 4 or 8 weeks has been demonstrated in three Phase 3 trials. Here, factors associated with virologic failure at Week 48 were evaluated post hoc. DESIGN AND METHODS: Data from 1039 adults...

Subject

Rilpivirine

Human immunodeficiency virus (HIV)

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!